Monsanto Co. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co.

MTC 3.120

+1.6%

Jan 16 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: jopawa who wrote (468)	11/7/1998 5:46:00 PM
From: Anthony Wong	Read Replies (1) of 2539

American College of Rheumatology 62nd National Meeting, November 8-12, 1998, San Diego, California ex2.excerptamedica.com GD Seale's scientific presentations on it's Cox-2 inhibitor will be on Tuesday, November 10 and Wednesday, November 11. Abstracts of papers on Cox-2 inhibitors presented by GD Searle researchers: SAFETY AND EFFICACY OF CELECOXIB, A SPECIFIC COX-2 INHIBITOR, IN PATIENTS WITH RHEUMATOID ARTHRITIS ex2.excerptamedica.com CELECOXIB, A SPECIFIC COX-2 INHIBITOR, LACKS SIGNIFICANT DRUG-DRUG INTERACTIONS WITH METHOTREXATE OR WARFARIN ex2.excerptamedica.com EFFICACY AND SAFETY OF CELECOXIB, A SPECIFIC COX-2 INHIBITOR, IN PATIENTS WITH RHEUMATOID ARTHRITIS ex2.excerptamedica.com EFFICACY, TOLERABILITY, AND SAFETY OF CELECOXIB, A SPECIFIC COX-2 INHIBITOR, IN OSTEOARTHRITIS ex2.excerptamedica.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next